Table 2.

Univariable associations between patient characteristics and CMV.

	N	n (%) with CMV	Hazard Ratio (95% Confidence Interval)	p-Value
Overall	102	37 (36.3)	--
Age, 5-year increase	--	--	0.95 (0.80–1.13)	0.52
Age
<65	54	21 (38.9)	1 (ref)	0.62
≥65	48	16 (33.3)	0.85 (0.44–1.62)
Race/ethnicity
African American	67	27 (40.3)	1 (ref)	0.58
White	27	7 (25.9)	0.66 (0.27–1.41)
Other	8	3 (37.5)	0.81 (0.22–2.16)
Cause of ESRD
Diabetes	46	18 (39.1)	1 (ref)	0.11
Hypertension	26	13 (50.0)	1.30 (0.63–2.60)
Other	30	6 (20.0)	0.50 (0.19–1.16)
Transplant type
DDKT	28	13 (46.4)	1 (ref)	0.02
DCD	71	22 (31.0)	1.62 (0.80–3.14)
LKT	3	2 (66.7)	5.07 (1.01–16.3)
History of hepatitis C
No	73	26 (35.6)	1 (ref)	0.89
Yes	29	11 (37.9)	0.95 (0.46–1.87)
History of hepatitis B
No	93	34 (36.6)	1 (ref)	0.97
Yes	9	3 (33.3)	1.02 (0.28–2.69)
Immunologic risk
No	92	34 (37.0)	1 (ref)	0.96
Yes	10	3 (30.0)	0.97 (0.26–2.57)
CMV risk
1	6	0 (0.0)	1 (ref)	0.28
2	48	17 (35.4)
3	48	20 (41.7)	1.41 (0.75–2.71)
cPRA > 0
0	94	33 (35.1)	1 (ref)	0.38
>0	8	4 (50.0)	1.54 (0.50–3.73)
Donor age, 5-year increase	--	--	1.05 (0.93–1.19)	0.44
Donor age
<40	45	15 (33.3)	1 (ref)	0.56
≥40	57	22 (38.6)	1.21 (0.64–2.36)
KDPI, 10-point increase	--	--	1.10 (0.96–1.27)	0.17
KDPI
<50	45	13 (28.9)	1 (ref)	0.32
≥50	54	22 (40.7)	1.40 (0.72–2.83)
Induction
<4 mg/kg	31	13 (41.9)	1 (ref)	0.18
>4 mg/kg	38	17 (44.7)	1.06 (0.52–2.20)
Basiliximab	33	7 (21.2)	0.50 (0.19–1.20)
Delayed graft function
No	71	28 (39.4)	1 (ref)	0.44
Yes	31	9 (29.0)	0.75 (0.34–1.52)